PTH-Related Peptide Market 2006: Clinical Trial Data, Therapeutic Comparisons, and Industry Growth Forecasts
Title: PTH-Related Peptide Market 2006: Clinical Trial Data, Therapeutic Comparisons, and Industry Growth Forecasts Abstract: The 2006 PTH-related peptide market, driven by clinical trial data for osteoporosis and hypoparathyroidism, demonstrated robust growth. Teriparatide (Forteo) dominated, leveraging superior anabolic bone formation vs. antiresorptives, despite injection-site limitations. Industry forecasts projected a CAGR of 8-12%, fueled by expanding therapeutic applications. Key differentiators included purity (>98% by HPLC), bioactivity, and cold-chain logistics. Brand comparisons highlighted Forteo’s regulatory edge over emerging analogs. Technical advantages (targeted osteoblast activation) outweighed drawbacks (high cost, storage at 2-8°C). Market trends emphasized GMP-certified manufacturing and rigorous batch-to-batch consistency for clinical efficacy.